Chicago, IL – June 6, 2025 – Gene Matrix, a U.S.-based biotechnology company, announces its global expansion and commitment to advancing personalized medicine and preventive care worldwide. The company is at the forefront of integrating genomics, pharmacogenomics, and artificial intelligence into healthcare systems—bridging the gap between cutting-edge science and everyday clinical practice.

Founded on the core belief that “your DNA holds the key to better health,” Gene Matrix delivers end-to-end solutions that combine scientific rigor, AI-powered platforms, and regulatory-grade laboratory systems. Its scalable and accessible model for precision medicine empowers both healthcare providers and patients to take a proactive role in managing health at the genetic level.

Pioneering a New Era in Genetic Healthcare

Gene Matrix is more than a diagnostics company — it is a comprehensive biotechnology ecosystem designed to help governments, hospitals, clinics, and individuals decode their genetic profiles and make informed health decisions.

The company’s growing portfolio of 12+ proprietary genetic panels includes:

• GenePGx – Pharmacogenomics panel for personalized drug response
• GeneCancer – Early detection and risk analysis for various cancers
• GeneMind – Mental health-focused panel identifying genetic predispositions
• GeneHealth – Cardiovascular and metabolic disease screening
• GeneDiet – Nutrigenomics insights for personalized diet plans
• GeneSport – Genetic analysis for athletic performance and injury prevention

These panels are available for clinical and direct-to-consumer use, allowing integration into existing healthcare practices or personal wellness journeys. The diagnostics are powered by AI engines capable of generating multilingual reports with real-time physician dashboards, making advanced genomics accessible even in decentralized settings.

A Vision for Global Health Transformation

Gene Matrix envisions a future where no patient is left behind due to lack of information. Through its AI-powered genomics infrastructure, the company is working to eliminate trial-and-error approaches in medicine by offering precise, affordable, and preventive diagnostics.

“Our goal is to eliminate guesswork in medicine,” said Tarek Younis, Founder and CEO of Gene Matrix. “We help physicians prescribe the right drug the first time, detect cancers before symptoms appear, and give every individual the power to understand their biology. We’re combining science, technology, and accessibility to reshape global healthcare.”

What Sets Gene Matrix Apart

Gene Matrix stands out through its turnkey platform that delivers:

• Complete End-to-End Solutions – From sample collection kits to AI analysis
• Global Compliance – Infrastructure aligned with HIPAA, GDPR, and ISO standards
• Scalable Deployment – Adaptable to public health systems, private clinics, or direct-to-consumer models
• Real-Time AI Reporting – Automated clinical dashboards and patient reports in multiple languages
• High Clinical Validity – Supported by CLIA-certified and CAP-accredited laboratory partners
• Population Health Tools – Predictive analytics and insights for governments and insurers

The platform’s flexibility allows it to operate across different regulatory environments while maintaining the integrity and accuracy of its diagnostics. Gene Matrix also offers white-label partnerships for governments and healthcare enterprises seeking to introduce genetic testing infrastructure within their systems.

International Reach and Local Engagement

Gene Matrix has already established operations and partnerships across multiple countries. In the United States, the company provides clinical diagnostics and direct-to-consumer genetic tests. Expansion into Europe, Asia, and the Middle East is underway, with customized deployment models tailored to regional healthcare infrastructures and compliance requirements.

By working closely with local healthcare providers, ministries of health, and insurance companies, Gene Matrix ensures that its technology is not only innovative but also culturally and operationally relevant in each market it enters.

Looking Ahead

As part of its global roadmap, Gene Matrix plans to launch additional panels targeting women’s health, rare genetic disorders, and infectious disease susceptibility. The company is also investing in R&D partnerships with universities and medical institutions to continually refine its AI algorithms and explore new diagnostic frontiers.

Furthermore, Gene Matrix is developing a secure digital platform that allows individuals to manage, share, and understand their genomic data while maintaining privacy and control. This initiative reflects the company’s long-term commitment to ethical innovation and patient empowerment.

For more information, please visit:

genematrix.io | genematrix.eu

For media and partnership inquiries:

Email: [email protected]

Media Contact
Company Name: Gene Matrix
Contact Person: Tarek Younis
Email: Send Email
Country: United States
Website: https://www.genematrix.io